Copyright
©The Author(s) 2022.
World J Cardiol. Jan 26, 2022; 14(1): 40-53
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40
Figure 3 The figure shows comparative major bleeding events with Fondaparinux and Enoxaparin.
The major bleeding events were noticed significantly lower as compared to Enoxaparin and thus its use was kindred with less major bleeding across all estimated glomerular filtration rate quartiles. eGFR: Estimated glomerular filtration rate.
- Citation: Khan MY, Ponde CK, Kumar V, Gaurav K. Fondaparinux: A cornerstone drug in acute coronary syndromes. World J Cardiol 2022; 14(1): 40-53
- URL: https://www.wjgnet.com/1949-8462/full/v14/i1/40.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i1.40